Holen Sie sich die Stockscreener-App
1.49
3.25%
-0.05
Vorhandelsmarkt:
1.41
-0.08
-5.37%
Schlusskurs vom Vortag:
$1.54
Offen:
$1.56
24-Stunden-Volumen:
7.35M
Relative Volume:
5.42
Marktkapitalisierung:
$39.17M
Einnahmen:
$1.79M
Nettoeinkommen (Verlust:
$-70.90M
KGV:
-0.0959
EPS:
-15.54
Netto-Cashflow:
$-34.95M
1W Leistung:
-32.27%
1M Leistung:
-22.80%
6M Leistung:
-50.66%
1J Leistung:
-73.49%
1-Tages-Spanne:
$1.34
$1.57
1-Wochen-Bereich:
$1.34
$2.88
52-Wochen-Spanne:
$1.26
$5.96
Senti Biosciences Inc Stock (SNTI) Company Profile
Firmenname
Senti Biosciences Inc
Sektor
Branche
Telefon
(650) 239-2030
Adresse
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Vergleichen Sie SNTI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
1.49 | 40.49M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-06 | Eingeleitet | Laidlaw | Buy |
| 2022-10-07 | Eingeleitet | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Aktie (SNTI) Neueste Nachrichten
Senti Biosciences: Understanding the Market Moves - StocksToTrade
Chardan Raises Price Target on Senti Biosciences to $13 From $12, Keeps Buy Rating - marketscreener.com
Check Out Senti Biosciences Inc (SNTI)’s Trade Data Rather Than the Analysts’ Views - Setenews
Senti Biosciences, Inc. (SNTI) Stock: Faces Decline Despite Groundbreaking FDA Designation - Menafn.com
Senti Biosciences Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biotech Stocks Today: FDA Shifts, ASH 2025 Winners and Market Close Recap (December 9, 2025) - ts2.tech
Unveiling Senti Biosciences: Shaping the Future of Cancer Therapy? - StocksToTrade
Why Is Gene Therapy Focused Senti Bio Stock Falling Today? - Benzinga
Lyft Stock Soars Following Strategic Euro Expansion Through FreeNow Acquisition - StocksToTrade
Senti Biosciences’ Strategic Moves Ripple Across Biotech Market - timothysykes.com
Senti Biosciences Secures FDA RMAT Designation For SENTI-202 - Nasdaq
Senti Biosciences Announces Positive Data From Ongoing SENTI-202 Trial, Stock Up - Nasdaq
Senti Announced Positive Phase 1 Data For SENTI-202 In Relapsed/ Refractory AML - Nasdaq
Senti Biosciences’ Surge: Buy or Wait? - timothysykes.com
Senti Bio’s SENTI-202 shows promising results in AML clinical trial By Investing.com - Investing.com Canada
Senti Biosciences Reports Promising Phase 1 Trial Results - TipRanks
Senti Bio’s SENTI-202 shows promising results in AML clinical trial - Investing.com
Senti Bio stock soars after positive cancer therapy trial results By Investing.com - Investing.com Canada
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile - The Manila Times
Senti Biosciences, Inc. Announces Initial Clinical Data for SENTI-202 - TradingView
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia - marketscreener.com
Senti Bio (Nasdaq: SNTI) gains FDA RMAT for SENTI-202 after 50% ORR in AML trial - Stock Titan
Is Senti Biosciences Inc a good long term investmentLong-Term Investment Plans & Small Investment Growth Plans - earlytimes.in
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Senti Biosciences, Inc. to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented At the American Society of Hematology Annual Meeting 2025 - marketscreener.com
Senti Biosciences, Inc. to Host Conference Call on Updated Clinical Results for SENTI-202 Prior to ASH Annual Meeting - Quiver Quantitative
Senti Bio (Nasdaq: SNTI) to host Dec. 9 webcast on updated SENTI-202 data from ASH 2025 - Stock Titan
How Senti Biosciences Inc. stock reacts to oil pricesJuly 2025 Price Swings & Capital Efficiency Focused Strategies - Newser
Senti Biosciences (SNTI) Stock Analysis Report | Financials & Insights - Benzinga
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - ADVFN
Form 8-KCurrent report - ADVFN
Senti Biosciences, Inc. (NASDAQ:SNTI) Receives $8.75 Consensus PT from Analysts - Defense World
Leerink Partners Initiates Coverage on Senti Biosciences (NASDAQ:SNTI) - Defense World
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study - MSN
Leerink Partners initiates coverage on Senti Biosciences stock with Outperform rating - Investing.com Australia
Leerink Partners Initiates Coverage of Senti Biosciences (SNTI) with Outperform Recommendation - Nasdaq
Leerink Partners initiates coverage on Senti Biosciences stock with Outperform rating By Investing.com - Investing.com South Africa
SNTI Stock Rating Update: Leerink Partners Initiates Coverage | - GuruFocus
Why Senti Biosciences Inc. stock is a must watch in 20252025 Breakouts & Breakdowns & Free Long-Term Investment Growth Plans - newser.com
Is Senti Biosciences Inc. stock vulnerable to regulatory risksJuly 2025 Closing Moves & Weekly High Return Forecasts - newser.com
Why Senti Biosciences Inc. stock could benefit from AI revolutionWeekly Gains Summary & Technical Entry and Exit Tips - newser.com
Is Senti Biosciences Inc. trending in predictive chart modelsQuarterly Market Summary & Expert Approved Momentum Ideas - newser.com
Combining machine learning predictions for Senti Biosciences Inc.Quarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
How Senti Biosciences Inc. stock benefits from global expansionEarnings Risk Summary & Growth Focused Stock Reports - newser.com
Finanzdaten der Senti Biosciences Inc-Aktie (SNTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):